Trial ID or NCT#



recruiting iconRECRUITING


This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

Official Title

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Eligibility Criteria

Ages Eligible for Study: Younger than 18 Months
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Jay Michael S. Balagtas
Neyssa Marina
Sheri Spunt

Contact us to find out if this trial is right for you.


Richard Fu
(650) 497-8815